A flattish Monday
With risk sentiment tepid and not really in the mood for anything thus far, it is leaving traders little to work with as we get things going on the new week.

A look at what’s driving Ripple
Global payments solution provider Ripple has been in the news the whole year for varied reasons. First, its prolonged legal battle with the Securities and Exchange Commission, which many didn’t expect to go on for this long, especially with Gary Gensler at the helm of the Commission. 

The US House of Representatives passed a bipartisan infrastructure bill late Friday, circa US$550bn. 
A second bill (circa $1.75tln) re tax and spending was not voted on yet. Next week the House is on a break so there is least a week’s wait for this. A ‚procedural‘ vote passed to tee up voting when the Reps.

NASDAQ up for the 10th consecutive trading day
The final numbers are showing:
For the trading week, the
The JPY is ending the day as the strongest of the majors while the GBP is the weakest.  

Price is closing lower on the week and gave up all the day gains
The USDCHF is not ending on a happy note for the buyers as the week’s trading moves toward the close. 

Forex news for New York trade on November 5, 2021:
Markets:
The non-farm payrolls report was solid across the board but not strong enough to shake anyone out of their beliefs. So markets continued to price out rate hikes and squeeze bond shorts. Once again, that led to yen buying in an unwind of some of the

Highlights to look out for
Monday, Nov 8
Tuesday, Nov 9
Wednesday, Nov 10
Thursday, Nov 11
Friday, Nov 12
economic calendar

Forex news from the European trading session – 5 November 2021
Headlines:
Markets:
– USD leads, AUD and GBP lag on the day
– European equities higher; S&P 500 futures up 0.2%

German state leaders warn that hospitals could soon be swamped
Adding that a new lockdown might be needed unless urgent action is taken to reverse the recent surge in cases. Here’s a chart to bring everyone up to speed:

Pfizer says that its pill, used, with an HIV drug, cut the risk of hospitalisation or death by 89% in high-risk adults exposed to COVID-19
This would be the second antiviral pill after Merck’s (which is reported to reduce risks of hospitalisation or death by around 50% with mild or moderate cases of COVID-19) to have